Today

Davis Commodities filed a Form 6‑K furnishing a press release (Exhibit 99.1) clarifying recent reports about a May 14, 2026 Singapore High Court order in a dispute between Raízen Trading SA and Carfax Commodities (Asia) Pte. The filing does not disclose whether Davis is directly named or quantify any exposure; more detail is needed to assess investor impact.

FDA accepted Grace's NDA for GTx-104 and set an April 23, 2026 PDUFA date.

Nano Dimension announced sale of MarkForged to Stratasys in an all-cash transaction (reported ~ $42M) and expects to reduce annualized cash burn by approximately $15M; transaction should improve near-term liquidity but market impact depends on company cash, revenue contribution of MarkForged, and timing/receipt of proceeds.

Stratasys furnished a press release (Exhibit 99.1) titled 'Agreement for Acquisition of Markforged, Inc.' The exhibit references an all-cash transaction (~$42.5M) and notes Markforged generated ~$70M in 2025; the 6-K is a short wrapper and the exhibit needs analyst review to confirm parties, payment mechanics, closing conditions and expected financial impact on Stratasys.

Positive Phase 2 Part B readout: mid-dose zumilokibart showed substantially higher EASI-75 and IGA responses vs placebo at Week 16 with mid-dose selected as planned Phase 3 dose and acceptable conjunctivitis rates versus higher doses.

Apogee entered a revenue participation sale with BXLS for $100M upfront (May 26, 2026) with additional tranche options and tiered revenue-share percentages; company removed cash‑runway guidance. This materially improves near‑term liquidity but creates long‑term revenue share obligations that could reduce future net product receipts if zumilokibart achieves high sales.

TSMC's board approved distribution of NT$155,595,147,126 (NT$6.00 per share) for 4Q2025, payable July 9, 2026. The filing provides amount, per-share figure, and payment date but lacks market-context (shares outstanding, price, FX) needed to assess yield and materiality.

Capri issued Q4/FY2026 results (Exhibit 99.1): total revenue of $796M (down ~3%), net debt improved to $222M from $1.4B, cash $135M, recorded a $65M IEEPA tariff refund receivable, and announced repurchase activity (text-truncated in filing). Company provided FY2027 low-single-digit revenue guidance and 40% adjusted EPS growth but did not provide a GAAP reconciliation for the non-GAAP outlook.

Nanobiotix issued ADSs, ordinary shares and pre-funded warrants, increasing dilution.

FINS sold 2.0M Series A preferred shares for $50M; purchaser gets two board seats.

Sold unregistered Class I shares and declared three monthly distributions.

Board stopped the RockawayX deal after finding material inconsistencies in RockawayX's financials.

Kyivstar disclosed it paid $80.8M to buy six Lviv solar plants, expanding green energy capacity and hedging electricity costs.

Nasdaq issued a Staff Delisting Determination after Vestand missed multiple 10-Q and 10-K filings.

Lincoln completed its IPO, raised $473.7M, and established public corporate structure.

BurTech closed an $80M IPO and funded a trust for a future business combination.

Shareholders approved a 3.8M-share increase to the company equity plan and officer exculpation amendment.

Company closed $225M convertible notes offering, creating potential equity dilution.

Azul's ADSs begin trading on NYSE American on June 1, 2026.

Quanterix named Anthony Catalano COO with cash and RSU compensation.